- The shares of Cano Health (NYSE: CANO) have received a $13 price target from Cowen. These are the details.
The shares of Cano Health (NYSE: CANO) have received a $13 price target from Cowen. And Cowen analyst Gary Taylor is maintaining an “Outperform” rating on the shares.
“CANO’s shift to industry-convention MRA revenue recognition boosts guided EBITDA materially to a new higher run-rate in 2022 & beyond. It also has the effect of driving restated 2021A EBITDA from 27m to 2022G of 235m (returning to 2020 s 8% margin on 3x revenue base),” wrote Taylor in a research note. “Even with the MRA tailwind that’s a big jump. If CANO can hit its 2022 guidance the stock represents significant value.”
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.